Biotech Values

[DewDiligence]

VRTX commits to test 12w Incivek+VX-222+ifn+ribavirin in phase-3:

http://finance.yahoo.com/news/Interim-Data-from-Phase-2-bw-3000077287.html?x=0&.v=1

On the basis of the results announced today and previously announced data from other treatment arms of the ZENITH study, Vertex intends to start a Phase 3 study to evaluate a total treatment duration of 12 weeks with this four-drug regimen in treatment naïve and relapser patients with genotype 1 chronic hepatitis C.

Here are the interim results from the phase-2 ZENITH study reported today at AASLD:



*50% (15/30) had undetectable hepatitis C virus at weeks 2 and 8 and were eligible to stop all treatment at week 12. Two people in the VX-222 (400 mg) treatment arm discontinued treatment before week 12 and did not achieve SVR12.

**38% (11/29) had undetectable hepatitis C virus at weeks 2 and 8 and were eligible to stop all treatment at week 12. Four people in the VX-222 (100 mg) treatment arm discontinued treatment before week 12 and two of them achieved SVR12.

+One person in the 12-week VX-222 (400 mg) treatment arm relapsed.

++Two people in the 12-week VX-222 (100 mg) treatment arm relapsed.